Estrogen Receptor Assay of Mammary Carcinomas: Effects of Testosterone-Estradiol-binding Globulin (TeBG) and Serum Estradiol-17β

1979 ◽  
Vol 72 (4) ◽  
pp. 564-570 ◽  
Author(s):  
John S. Meyer ◽  
Sue C. Stevens ◽  
Nancy Vandillen ◽  
Wilma L. White
2020 ◽  
Vol 4 (4) ◽  
Author(s):  
Pedro H V Carvalho ◽  
Mariana F Westphalen ◽  
Jonathan A Campbell ◽  
Tara L Felix

Abstract The objectives of the study were to determine the effect of coated or noncoated hormone implants on growth performance, carcass characteristics, and serum estradiol-17β (E2) concentrations of Holstein steers fed a grain-based diet for 112 d. Seventy-nine Holstein steers [average initial body weight (BW) = 452 ± 5.5 kg] were stratified by BW and allotted to one of two treatments: 1) Holstein steers implanted with a coated implant containing 200 mg of trenbolone acetate (TBA) and 40 mg E2 (Revalor-XS (Merck Animal Health; Summit, NJ)] on day 0 (XS) or 2) Holstein steers implanted two times (days 0 and 56) with a noncoated implant containing 80 mg of TBA and 16 mg of E2 [(2IS) Revalor-IS (Merck Animal Health)]. Data were analyzed using the MIXED procedure of SAS (SAS Inst. Inc., Cary, NC). There was no effect (P ≥ 0.71) of implant strategy on initial, middle, and final BW. No effect (P ≥ 0.12) of implant strategy was observed on average daily gain, dry matter intake, or gain-to-feed ratio. There were no effects (P ≥ 0.11) of implant strategy on carcass characteristics. There was an implant × day interaction (P < 0.01) for the circulation of serum E2 concentrations. Serum E2 concentration increased similarly 14 d after Holstein steers were implanted, regardless of implant strategy. At 28 d, after steers were implanted, steers in the XS group had less serum E2 concentration than Holstein steers in the 2IS group. However, at 56 d after the first implantation, both groups, once again, had similar serum E2 concentrations and E2 concentrations were less on day 56 than day 28 for both strategies. Holstein steers implanted with 2IS had greater serum E2 concentration on day 70 and E2 concentrations remained greater than serum E2 of Holstein steers implanted XS for the duration of the trial (day 112). In summary, there was no effect of coated or two doses of noncoated implant on growth performance or carcass characteristics of Holstein steers.


2020 ◽  
Author(s):  
Ka-Ying Wong ◽  
Liping Zhou ◽  
Wenxuan Yu ◽  
Christina Chui Wa Poon ◽  
Man-Sau Wong

Abstract Background: Er-Xian decoction (EXD), a traditional Chinese Medicine for managing menopausal syndrome and osteoporosis in China, could exert osteoprotective action via activation of estrogen receptor (ERs) and regulation of serum estradiol without causing severe side effects. However, no fundamental studies have explored its potential interaction in the combined use of prescription drugs, Selective Estrogen Receptor Modulators (SERMs), regarding the osteogenic and uterotrophic effects. The present study evaluated the estrogenic effects of EXD and its potential interactions with tamoxifen and raloxifene in bone and uterus using a mature ovariectomized (OVX) Sprague-Dawley (SD) rat model and human osteoblastic MG-63 cells. Methods: Six-month-old female SD rats were randomly assigned to Sham-operated group or seven OVX groups: vehicle, 17ß-estradiol (E2, 1.0 mg/kg.day), Tamoxifen (Tamo, 1.0 mg/kg.day), Raloxifene (Ralo, 3.0 mg/kg.day), EXD (EXD, 1.6 g/kg.day), EXD+Tamoxifen (EXD+Tamo) and EXD+Raloxifene (EXD+Ralo). The effect of EXD on bodyweight, bone mineral density (BMD), bone microarchitecture, biochemical analysis of serum and urine, and uterus were evaluated. In addition, Alkaline phosphatase assay and activation of estrogen-responsive element mediated by EXD and in its combination with SERMs were investigated in MG-63 cells. Results: In vivo, EXD could interact with SERMs to modulate the serum estradiol, follicle-stimulating hormone, osteocalcin level as well as BMD and bone properties in OVX rats. Moreover, EXD could relieve the uterotrophic effect of SERMs. In vitro, EXD crude extract and EXD-treated serum could promote ALP activity. In particular, EXD-treated serum could interact with SERMs on regulating ALP activity in MG-63 cells. Conclusion: Our study demonstrated that EXD in vivo and EXD-treated serum in vitro did not weaken the osteogenic effect of SERMs. Interestingly, EXD seems to ameliorate the uterotrophic effects of SERMs. Therefore, the combined use of EXD and SERMs may be considered safe and effective in managing postmenopausal osteoporosis.


1982 ◽  
Vol 16 (5) ◽  
pp. 661-671 ◽  
Author(s):  
L.G. Van Doorn ◽  
J. Berenschot-Roozendaal ◽  
J. Poortman ◽  
J.H.H. Thussen ◽  
F. Schwarz

1998 ◽  
Vol 44 (3) ◽  
pp. 671-674 ◽  
Author(s):  
Linda M Thienpont ◽  
André P De Leenheer

2012 ◽  
Vol 8 (3) ◽  
pp. 144-148 ◽  
Author(s):  
Shannon Wills ◽  
Anita Ravipati ◽  
Padmaja Venuturumilli ◽  
Cynthia Kresge ◽  
Elizabeth Folkerd ◽  
...  

The authors conclude that intravaginal estradiol treatment, regardless of type, results in elevated circulating E2 levels in this population and should be used with caution.


Sign in / Sign up

Export Citation Format

Share Document